Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 3.
Del Rosso James Q JQ, Lam Lauren L, Dasilva Diego Ruiz DR, Burshtein Joshua J et al.
Despite greater awareness of hidradenitis suppurativa (HS) as a well-defined, chronic inflammatory skin disorder that can flare unpredictably and be highly symptomatic, both patients and clinicians face challenges in facilitating care that is expedient, effective, reasonably safe, and accessible. Fortunately, since the approval of the injectable anti-tumor necrosis factor (TNF)-α agent, adalimumab, in 2015 by the United States Food and Drug Administration (FDA), treating HS inflammation that is not visible clinically but is occurring steadily and progressively below the surface of the skin has proven to be of extreme importance to patients, especially as related to long-term management. The mechanism of action (MOA) of properly selected biologic therapy inhibits both the inflammation associated with active primary HS skin lesions and the subsequent irreversible fibrotic and cicatricial dermal sequelae that form due to destructive changes occurring more deeply within inflamed HS lesions. Over the past decade, the ability to therapeutically and pharmacologically halt the progression of irreversible tissue destruction in HS has emerged, first with anti-TNF-α therapy and then later with anti-interleukin (IL)-17 therapies. In this third article of a 4-part series on HS, information on therapeutic management is expanded to include secukinumab and bimekizumab, both FDA-approved anti-IL-17 monoclonal antibodies for moderate-to-severe HS in adults. Additional topics covered in this article embrace other MOAs and cascades of inflammation that are believed to markedly contribute to HS pathophysiology and provide therapeutic benefit, including systemic Janus kinase inhibitors and glucagon-like peptide-1 receptor agonists. Ultimately, the goal of this 4-part article series is to provide a substantial scientific foundation on the disease state coupled with a practical, reasonably comprehensive, and clinically useful collection of source information that can serve as a valuable "guidance tool" to assist clinicians in managing HS. As stated in the first article of this series, multiple authors have separately contributed individual sections inclusive of supporting references. All authors were primarily responsible for their individual sections but also participated in the review and finalization of the complete series of articles. The order of the authors reflects the order of appearance of their primary sections in the 4-part article series.